Researchers are exploring new options for patients with relapsed or refractory hairy cell leukemia, including chimeric ...

The first-in-human combined bladder and kidney transplant, reported in June 2026, restored spontaneous voiding and stable ...

Chennai, Oct. 31 -- Highlights: ...

Casgevy gene therapy for UK children was extended to patients aged five and over by the MHRA on October 29, 2026; a milestone ...

UHN Foundation proudly announces a landmark $35 million gift from Toronto's Ajmera family, raising their cumulative giving to $62 million and establishing the Ajmera Transplant Institute at University ...

Change vs. the prior quarter call: Q2 guidance was raised to $490 million-$500 million revenue and $66 million-$78 million adjusted EBITDA; in Q3, management raised those ranges to $520 million-$530 ...

A new review outlines how engineered exosome nanocarriers could deliver drugs precisely to diseased heart tissue, while major ...

CareDx (NASDAQ:CDNA) reported third-quarter 2026 revenue growth of 39% as testing volumes increased, driven by its transplant ...

Democrats register a seven-point lead over Republicans in the race for control of Congress, while the president's disapproval rating reaches a record high of 60% according to a new national Nbc News ...

Formula 1 returns with the Mexico GP qualifying. Today, Saturday, October 31, the Circus stops in Mexico City after Antonelli's triumph in Austin. The Mercedes driver is one step away from winning the ...

Natera is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the ...

Morgan Stanley Adjusts Price Target on Natera to $435 From $355, Maintains Overweight Rating MT Oct. 09 Natera, Inc. Receives FDA Breakthrough Device Designation for Its Multi-Cancer Early Detection ...